158 related articles for article (PubMed ID: 29898969)
1. Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults.
Ecay-Torres M; Estanga A; Tainta M; Izagirre A; Garcia-Sebastian M; Villanua J; Clerigue M; Iriondo A; Urreta I; Arrospide A; Díaz-Mardomingo C; Kivipelto M; Martinez-Lage P
Neurology; 2018 Jul; 91(3):e217-e226. PubMed ID: 29898969
[TBL] [Abstract][Full Text] [Related]
2. CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia.
Enache D; Solomon A; Cavallin L; Kåreholt I; Kramberger MG; Aarsland D; Kivipelto M; Eriksdotter M; Winblad B; Jelic V
Neurobiol Aging; 2016 Jun; 42():124-31. PubMed ID: 27143429
[TBL] [Abstract][Full Text] [Related]
3. CAIDE Score, Alzheimer's Disease Pathology, and Cognition in Cognitively Normal Adults: The CABLE Study.
Guo ZX; Liu F; Wang FY; Ou YN; Huang LY; Hu H; Wang ZB; Fu Y; Gao PY; Tan L; Yu JT
J Alzheimers Dis; 2024; 99(4):1273-1283. PubMed ID: 38728186
[TBL] [Abstract][Full Text] [Related]
4. Midlife CAIDE dementia risk score and dementia-related brain changes up to 30 years later on magnetic resonance imaging.
Vuorinen M; Spulber G; Damangir S; Niskanen E; Ngandu T; Soininen H; Kivipelto M; Solomon A
J Alzheimers Dis; 2015; 44(1):93-101. PubMed ID: 25190628
[TBL] [Abstract][Full Text] [Related]
5. Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, and cognition.
Stephen R; Liu Y; Ngandu T; Rinne JO; Kemppainen N; Parkkola R; Laatikainen T; Paajanen T; Hänninen T; Strandberg T; Antikainen R; Tuomilehto J; Keinänen Kiukaanniemi S; Vanninen R; Helisalmi S; Levälahti E; Kivipelto M; Soininen H; Solomon A
J Alzheimers Dis; 2017; 59(2):695-705. PubMed ID: 28671114
[TBL] [Abstract][Full Text] [Related]
6. Global Vascular Risk Score and CAIDE Dementia Risk Score Predict Cognitive Function in the Northern Manhattan Study.
Rundek T; Gardener H; Dias Saporta AS; Loewenstein DA; Duara R; Wright CB; Dong C; Levin B; Elkind MSV; Sacco RL
J Alzheimers Dis; 2020; 73(3):1221-1231. PubMed ID: 31884476
[TBL] [Abstract][Full Text] [Related]
7. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline.
Bos I; Verhey FR; Ramakers IHGB; Jacobs HIL; Soininen H; Freund-Levi Y; Hampel H; Tsolaki M; Wallin ÅK; van Buchem MA; Oleksik A; Verbeek MM; Olde Rikkert M; van der Flier WM; Scheltens P; Aalten P; Visser PJ; Vos SJB
Alzheimers Res Ther; 2017 Dec; 9(1):101. PubMed ID: 29284531
[TBL] [Abstract][Full Text] [Related]
8. Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort.
Salvadó G; Brugulat-Serrat A; Sudre CH; Grau-Rivera O; Suárez-Calvet M; Falcon C; Fauria K; Cardoso MJ; Barkhof F; Molinuevo JL; Gispert JD;
Alzheimers Res Ther; 2019 Jan; 11(1):12. PubMed ID: 30678723
[TBL] [Abstract][Full Text] [Related]
9. Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment.
Gonzales MM; Insel PS; Nelson C; Tosun D; Schöll M; Mattsson N; Sacuiu S; Bickford D; Weiner MW; Mackin RS;
Int J Geriatr Psychiatry; 2018 Oct; 33(10):1305-1311. PubMed ID: 29953668
[TBL] [Abstract][Full Text] [Related]
10. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
[TBL] [Abstract][Full Text] [Related]
11. Change in CAIDE Dementia Risk Score and Neuroimaging Biomarkers During a 2-Year Multidomain Lifestyle Randomized Controlled Trial: Results of a Post-Hoc Subgroup Analysis.
Stephen R; Ngandu T; Liu Y; Peltonen M; Antikainen R; Kemppainen N; Laatikainen T; Lötjönen J; Rinne J; Strandberg T; Tuomilehto J; Vanninen R; Soininen H; Kivipelto M; Solomon A;
J Gerontol A Biol Sci Med Sci; 2021 Jul; 76(8):1407-1414. PubMed ID: 33970268
[TBL] [Abstract][Full Text] [Related]
12. Differential Effects of
Rosenich E; Bransby L; Yassi N; Fripp J; Laws SM; Martins RN; Fowler C; Rainey-Smith SR; Rowe CC; Masters CL; Maruff P; Lim YY
Neurology; 2022 Apr; 98(17):e1704-e1715. PubMed ID: 35169009
[TBL] [Abstract][Full Text] [Related]
13. Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults.
Nation DA; Edmonds EC; Bangen KJ; Delano-Wood L; Scanlon BK; Han SD; Edland SD; Salmon DP; Galasko DR; Bondi MW;
JAMA Neurol; 2015 May; 72(5):546-53. PubMed ID: 25822631
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
[TBL] [Abstract][Full Text] [Related]
16. CAIDE dementia risk score relates to severity and progression of cerebral small vessel disease in healthy midlife adults: the PREVENT-Dementia study.
Low A; Prats-Sedano MA; Stefaniak JD; McKiernan EF; Carter SF; Douvani ME; Mak E; Su L; Stupart O; Muniz G; Ritchie K; Ritchie CW; Markus HS; O'Brien JT
J Neurol Neurosurg Psychiatry; 2022 May; 93(5):481-490. PubMed ID: 35135868
[TBL] [Abstract][Full Text] [Related]
17. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.
Kester MI; Goos JD; Teunissen CE; Benedictus MR; Bouwman FH; Wattjes MP; Barkhof F; Scheltens P; van der Flier WM
JAMA Neurol; 2014 Jul; 71(7):855-62. PubMed ID: 24818585
[TBL] [Abstract][Full Text] [Related]
18. Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.
Soldan A; Pettigrew C; Cai Q; Wang MC; Moghekar AR; O'Brien RJ; Selnes OA; Albert MS;
JAMA Neurol; 2016 Jun; 73(6):698-705. PubMed ID: 27064267
[TBL] [Abstract][Full Text] [Related]
19. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
[TBL] [Abstract][Full Text] [Related]
20. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
